Based on these studies several genomic alterations have been reported to correlate with prognosis including amplification of the MYCN oncogene (found in 30% of NB) [1,7], gains of 17q (>50%) and loss of 1p36 (30–35%) [1,8,9]. The gene discussed is MYCN; the disease is neuroblastoma.